New trial across Europe shows versatility of ImaginAb’s CD8 ImmunoPET technology
ImaginAb Inc, a market leading biotechnology company focused on developing next generation imaging and therapeutic radiopharmaceuticals (RPT) has today announced the dosing of the first patient in an imaging cohort of a Roche sponsored, open-label Phase 1b study of Glofitamab and Atezolizumab (Tecentriq®) or Polatuzumab Vedotin (Polivy®) in adult patients with relapsed/refractory B-Cell Non-Hodgkin’s Lymphoma.
The imaging sub-study, in which ImaginAb’s CD8 ImmunoPET imaging technology is used for the first time in a company sponsored study involving a haematological malignancy forms part of a larger multi-centre study run by Roche in 17 sites across 5 countries. As part of the study, ImaginAb’s CD8 ImmunoPET Imaging technology will be used in trial sites across several European centres including in the UK, Belgium, Spain, Italy and Denmark.
The announcement builds on preclinical validation studies, which led to the long-term collaboration between both companies, which started in July 2019.
Since then both organisations have worked closely to support the establishment of robust manufacturing and distribution chains in Europe that enable ImaginAb to supply multiple clinical sites.
Commenting on the development, Ian Wilson, Chief Executive Officer of ImaginAb stated:
“The announcement today, which sees our technology supporting such an important trial across multiple sites will help to validate the benefits that CD8 ImmunoPET brings; namely that it enables quicker identification of drug efficacy, potentially reducing the length of trials and allowing new therapies to advance to market quicker”.
Wilson continued “ImaginAb has a clear aim to become the lead in diagnostic and treatment choices, transforming patient care and helping patients live better and healthier lives. We believe this study will advance that goal and is a clear indication that not only is our technology gaining wider acceptance, but many others share our vision and benefits that our CD8 ImmunoPET technology offers”.
William Le, VP Operations at ImaginAb commented “The Roche team has offered invaluable feedback and assistance that allowed us to establish a Quality Management System. We look forward to continuing to work closely with them in partnership in both this and future studies"
ENDS
